User:Mr. Ibrahem/Daprodustat

Daprodustat, sold under the brand name Duvroq among others, is a medication used to treat low red blood cells due to chronic kidney disease. It is used in those who have been on dialysis for more than four months. It is taken by mouth. It is used to reduce the need for blood transfusions.

Common side effects include high blood pressure, blood clots, and abdominal pain. Other side effects may include worsening heart failure and upper gastrointestinal bleeding. Use may increase the risk of death. It is not recommended in those with active cancer. It interacts with medications that affect CYP2C8. Use in pregnancy may harm the baby. It is a hypoxia-inducible factor prolyl hydroxylase inhibitor which works by increasing erythropoietin.

Daprodustat was approved for medical use in Japan in 2020, and the United States in 2023. It is the first by mouth treatment for low red blood cells caused by kidney disease. Previously injectable erythropoiesis-stimulating agents were used for this purpose.